Physician profile
John V Barton
NPI 1841233095
$4,804.53
in general payments reported to CMS, 2019-2025
30 companies · $590 in 2025
The $590 reported for 2025 was more than what 93% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $938 · 2021: $919 · 2022: $739 · 2023: $716 · 2024: $390 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $666.68 | 2021-2024 | Vraylar |
| Sunovion Pharmaceuticals INC. | $614.07 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $496.72 | 2021-2023 | Dupixent |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $446.70 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $332.99 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $326.06 | 2019-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $300.92 | 2019-2024 | Rexulti, Abilify Maintena |
| Pfizer INC. | $280.90 | 2020-2024 | |
| Allergan, INC. | $199.44 | 2020 | |
| Axsome Therapeutics, INC. | $184.59 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $168.39 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $97.52 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $92.10 | 2022-2024 | Breztri, Farxiga |
| Ucb, INC. | $87.86 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.32 | 2019-2024 | Xifaxan, Trulance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $59.64 | 2022-2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $40.50 | 2019-2020 | |
| Merz North America, INC. | $39.62 | 2019-2020 | |
| Tolmar, INC. | $39.16 | 2024 | |
| Azurity Pharmaceuticals, INC. | $36.43 | 2025 | Azmiro |
| Novo Nordisk INC | $35.81 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $34.32 | 2024-2025 | Voquezna |
| Adlon Therapeutics L.P. | $33.12 | 2021 | |
| Eisai INC. | $24.68 | 2021 | |
| Supernus Pharmaceuticals, INC. | $20.86 | 2022 | |
| Antares Pharma, INC. | $19.50 | 2023 | Tlando, Nocdurna, Xyosted |
| Biohaven Pharmaceuticals, INC. | $14.09 | 2021 | |
| Lundbeck LLC | $13.61 | 2022 | |
| Merck Sharp & Dohme LLC | $13.58 | 2019 | |
| Mylan Specialty L.P. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.